Symbiomix Therapeutics LLC, which saw its single asset, Solosec (secnidazole, previously SYM-1219), approved by the FDA last month to treat bacterial vaginosis (BV), agreed to a buyout by Lupin Inc., the U.S. subsidiary of Mumbai-based Lupin Ltd., for $150 million, including $50 million up front. Lupin, which has a global presence but focuses largely on generics, earlier this year took an option to acquire privately held Symbiomix, which specialized in therapies to treat gynecologic infections.